Zacks: Analysts Expect TearLab Corporation (TEAR) Will Announce Quarterly Sales of $6.94 Million
Equities analysts forecast that TearLab Corporation (NASDAQ:TEAR) (TSE:TLB) will announce $6.94 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for TearLab Corporation’s earnings, with the lowest sales estimate coming in at $6.80 million and the highest estimate coming in at $7.07 million. TearLab Corporation reported sales of $7.22 million during the same quarter last year, which indicates a negative year over year growth rate of 3.9%. The business is expected to announce its next earnings report on Monday, November 6th.
On average, analysts expect that TearLab Corporation will report full year sales of $6.94 million for the current financial year, with estimates ranging from $27.60 million to $28.01 million. For the next financial year, analysts anticipate that the business will report sales of $29.91 million per share, with estimates ranging from $29.81 million to $30.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for TearLab Corporation.
TearLab Corporation (NASDAQ:TEAR) (TSE:TLB) last posted its quarterly earnings data on Monday, August 14th. The medical research company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.07. The company had revenue of $7 million during the quarter, compared to the consensus estimate of $6.86 million. During the same quarter last year, the firm earned ($0.08) EPS. The business’s revenue for the quarter was up 1.4% on a year-over-year basis.
Several equities analysts have recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of TearLab Corporation in a research note on Tuesday, May 16th. Zacks Investment Research downgraded shares of TearLab Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, May 16th. Finally, Rodman & Renshaw dropped their price target on shares of TearLab Corporation from $12.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, May 16th. Five research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus price target of $4.90.
TRADEMARK VIOLATION WARNING: “Zacks: Analysts Expect TearLab Corporation (TEAR) Will Announce Quarterly Sales of $6.94 Million” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/09/09/zacks-analysts-expect-tearlab-corporation-tear-will-announce-quarterly-sales-of-6-94-million.html.
Shares of TearLab Corporation (NASDAQ:TEAR) opened at 1.36 on Friday. TearLab Corporation has a 12-month low of $1.20 and a 12-month high of $7.70. The firm’s market cap is $7.81 million. The firm’s 50-day moving average is $1.95 and its 200-day moving average is $2.37.
TearLab Corporation Company Profile
TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TearLab Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corporation and related companies with MarketBeat.com's FREE daily email newsletter.